Vitruvias Therapeutics is voluntarily recalling Lot 504950 of Thyroid Tablets, USP 30 mg after testing confirmed the batch may be superpotent with excess active hormone.123 The recall affects 1,955 sold units distributed nationwide between January and September 2025, with potential health risks including hyperthyroidism symptoms.4513 No adverse events have been reported as of the August 23 recall notice, but the company urges patients not to stop medication without consulting healthcare providers.6714 The superpotency represents a quality control failure that could cause patient harm, requiring transparent corrective action to restore trust.213
THREATPatient harm from superpotent thyroid medication could lead to serious adverse events including hyperthyroidism, weight loss, muscle weakness and rapid heart rate, particularly dangerous for older adults, pregnant women and infants.1318
THREATRegulatory scrutiny and potential enforcement action if recall procedures are not followed correctly or if adverse events emerge after the recall notice.8
THREATFinancial liability from the recall of 1,955 sold units and potential compensation claims if patients are harmed.412
OPPORTUNITYDemonstrating proactive patient safety commitment through voluntary recall and transparent communication could build trust with regulators and healthcare providers.189
Best response strategy
REBUILD The superpotency represents a quality control failure that could cause patient harm, requiring transparent corrective action to restore trust.213 Voluntary recall with FDA knowledge demonstrates proactive responsibility but does not eliminate the duty-of-care failure.18 Transparent communication about corrective actions is essential to demonstrate commitment to preventing recurrence.9
Who is watching, and what each expects from the response:
customersPotential health risks from superpotent medication and need for safe treatment continuation.21318
regulatorCompliance with recall procedures and patient safety oversight.8
mediaAccuracy in reporting the recall scope and patient safety guidance.12613
employeesCompany viability and job security amid recall and potential reputational damage.11
investorsFinancial impact of recall and potential liability from adverse events.412
Suggested response plan
T+0-4h
Phase 1 — Contain & verify
Outcome: All internal communications frozen; recall facts verified against registry; holding statement ready for immediate publication.123456
comms
Freeze all uncoordinated external communications. Verify batch details (Lot 504950, NDC 69680-166-00, expiration 30 September 2026), distribution timeline (31 January 2025 to 30 September 2025), and sold units count (1,955) against internal records. Prepare holding statement acknowledging recall, patient safety priority, and contact information for questions.
Legal reviews and approves holding statement for regulatory compliance.
Medical affairs confirms patient safety guidance language.
Care team briefed on recall facts and contact protocols.
Done when: Zero uncoordinated external communications; holding statement approved by legal and ready for publication; recall facts verified against internal records.
T+4-12h
Phase 2 — Respond with transparency
Outcome: Comprehensive recall statement published across all channels; FDA notified; patient safety guidance disseminated to healthcare providers.78915
comms
Publish the full recall statement on website and via press release. Notify FDA of publication. Activate patient support channels with clear guidance for affected customers.
Publish detailed recall notice on company website with lot information and safety guidance.
Distribute press release to healthcare and consumer media outlets.
Notify FDA of public communication completion.
Activate patient support line with scripts for safe medication continuation guidance.
Done when: Recall statement live on website and distributed to media; FDA acknowledgement received; patient support team briefed with care scripts.
“Vitruvias Therapeutics is voluntarily recalling Lot 504950 of Thyroid Tablets, USP 30 mg due to potential superpotency.123 Patient safety is our highest priority. We have received no reports of adverse events related to this lot.614 Patients using tablets from this lot should NOT stop taking their medication without first consulting their healthcare provider.7 We are working with the FDA and have notified our distribution partners.89 Consumers with questions should contact us at the number below.15 We are arranging for destruction of all recalled product and will implement enhanced quality controls to prevent recurrence.9” website statementpress releasedirect outreach
T+1-3 days
Phase 3 — Manage stakeholder outreach
Outcome: All affected stakeholders have received targeted communications; healthcare providers are armed with guidance; media inquiries are managed consistently.91518
support
Execute targeted outreach to healthcare providers, pharmacies, and patient advocacy groups with recall details and safety guidance, while monitoring and responding to media inquiries.
Distribute recall notices to pharmacies and healthcare providers via email and fax.
Brief patient advocacy groups on recall details and safety guidance for vulnerable populations.
Monitor media coverage and respond to all inquiries with consistent messaging.
Done when: Healthcare provider outreach completed; pharmacy notifications acknowledged; media inquiry response rate maintained at 100% within 4 hours.
T+2-4 weeks
Phase 4 — Recover through corrective action
Outcome: Enhanced quality control measures implemented; recall process reviewed for improvements; trust rebuilt through transparent reporting of corrective actions.213
operations
Implement enhanced quality control testing protocols. Conduct root cause analysis of the superpotency issue. Publish a transparent report on corrective actions taken.
Conduct root cause analysis of the superpotency detection failure.
Implement enhanced potency testing for all thyroid tablet batches.
Publish transparent report on quality control improvements and preventive measures.
Done when: New quality control protocols implemented across all production lines; root cause analysis completed; corrective action report published on company website.
Evidence sources (9)
Everything this briefing cites — ANCHOR started the story, CONTEXT backs it without naming the brand.
Your crisis desk is ready — claim it to respond. Claiming is free — your response strategy & plan become collaborative, and you get the option to display your response & status updates on this page.
One short, factual update when this story develops — nothing else, from over:heard.
Email updates
By subscribing you consent to receive email updates about this story. Double opt-in: nothing is sent until you confirm from your inbox. Unsubscribe anytime — one click in every email.
Push notifications
No email needed — alerts appear on this device.
Not vitruvias.com? See what over:heard would flag for your brand.
Start free →
Independent media-monitoring briefing compiled by over:heard radar from public coverage. Assessments are decision support —
not statements by, or affiliation with, the brands mentioned. · Built from public sources, cited.
Every brand has a free, permanent right of reply —
editorial policy
· Powered by over:heard by wise:able
